Understanding how ZNF397 deficiency affects prostate cancer treatment resistance
Official title: Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate Cancer
Funded at Yale University · NIH-11235240 · Data updated 2026-11-12
This study is looking at how a missing ZNF397 gene affects prostate cancer cells, especially the tough kind that doesn't respond to standard treatments, to find new ways to help patients with advanced prostate cancer get better care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $397,668 |
| NIH project number | 7R01CA288820-02 |
| Project ID | NIH-11235240 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who may be experiencing resistance to androgen receptor-targeted therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those not experiencing treatment resistance may not benefit from this research.
What this research studies
This research investigates how a deficiency in the ZNF397 gene influences the behavior of prostate cancer cells, particularly their ability to change and resist treatments. By focusing on the aggressive form of prostate cancer known as metastatic castration-resistant prostate cancer (mCRPC), the study aims to uncover the mechanisms that allow these cancer cells to evade therapies targeting the androgen receptor. The researchers will explore the role of TET2, a gene that may serve as a new target for overcoming treatment resistance, potentially leading to more effective therapies for patients with advanced prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with advanced prostate cancer.
How similar studies have gone: Other research has shown promising results in targeting similar mechanisms of treatment resistance in cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Mu, Ping — Yale University
- Study coordinator: Mu, Ping
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.